Bone Biologics Corporation
BBLG
Since
Headquarters:
Exchange:
Industry:
Number of Employees:
Current Fiscal Year:
Market Cap:
Price per Share:
Quarterly Dividend per Share:
Price History
Latest Prices
Date | Open | High | Low | Close |
---|---|---|---|---|
2025-06-16 | 5 | 5 | 4.7721 | 4.94 |
2025-06-13 | 5.27 | 5.3252 | 4.7 | 4.7694 |
2025-06-12 | 4.86 | 5.4792 | 4.85 | 5.28 |
2025-06-11 | 5.41 | 5.4811 | 4.8501 | 4.91 |
2025-06-10 | 4.49 | 5.7713 | 4.33 | 5.56 |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.